Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taisho Acquires BMS Indonesia, OTC Assets; Price Tag Too High, Say Japanese Analysts

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Taisho Pharmaceutical, the largest OTC drug maker in Japan, has reached an agreement to acquire most outstanding shares of PT Bristol-Myers Squibb Indonesia and trademarks and other brand assets held in Asia by BMS, for roughly ¥28 billion ($310 million), Taisho announced Sept. 15
Advertisement

Related Content

Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week
Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week
Bristol-Myers Squibb To Sell Australian Manufacturing Facility To Generics Maker Sigma
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Fujifilm’s Tender Offer For Toyama Chemical Begins (Part 2 Of 2)
Fujifilm’s Tender Offer For Toyama Chemical Begins (Part 2 Of 2)
Advertisement
UsernamePublicRestriction

Register

SC072780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel